Do we need another short-acting beta-blocker? A definite maybe…

During the 50years since the development of the first nonselective β blockers by James Black, evolving research has led to the subsequent introduction on the market of a multitude of agents with various β receptor antagonistic properties. We have learned that β1 selective agents offer the advantage of a lesser effect on the bronchial and vascular territories and are currently the preferred agents in patients with coronary artery disease. Their cardiac protective effect has been widely recognized when part of a chronic regimen for patients who sustained a myocardial infarction, where besides a symptomatic effect, they have demonstrated a survival benefit.

http://ift.tt/2mWy8B5